16景峰01债券

Search documents
湖南景峰医药股份有限公司股票交易异常波动的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-09-05 04:49
Core Viewpoint - The company, Hunan Jingfeng Pharmaceutical Co., Ltd., is undergoing a pre-restructuring process, facing significant uncertainties regarding its ability to enter formal restructuring and the potential outcomes of this process [2][8]. Group 1: Stock Trading and Financial Performance - The company's stock (ST Jingfeng, stock code: 000908) experienced an abnormal trading fluctuation, with a cumulative closing price deviation of 13.75% over two consecutive trading days [3]. - For the first half of 2025, the company reported a revenue of 183.39 million yuan, a decrease of 9.47% year-on-year, and a net profit attributable to shareholders of -32.57 million yuan, an increase of 1.47% year-on-year [7]. Group 2: Restructuring Process - The company has entered a pre-restructuring phase, but there is uncertainty regarding whether it will proceed to formal restructuring due to the complex review process [2][8]. - The company has signed a restructuring investment agreement with CSPC Pharmaceutical Group, which has been selected as a pre-restructuring investor, but multiple uncertainties remain regarding the final restructuring plan and related financial arrangements [2][8]. Group 3: Debt Obligations - The company has not repaid the principal and interest of the "16 Jingfeng 01" bond, which amounts to 295 million yuan, and has reached a debt waiver agreement with five fund management representatives, waiving 110 million yuan of the principal [9]. - After the waiver, the remaining unpaid principal of the "16 Jingfeng 01" bond is 185 million yuan [9].
湖南景峰医药股份有限公司
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-08-24 22:20
Core Viewpoint - The company, Hunan Jingfeng Pharmaceutical Co., Ltd., has reported no cash dividends or stock bonuses for the current reporting period, and it has acknowledged accounting errors that require adjustments to previous financial statements [3][4]. Company Overview - Hunan Jingfeng Pharmaceutical Co., Ltd. has not experienced significant changes in its operational status during the reporting period [6]. Financial Data and Indicators - The company issued "16 Jingfeng 01" bonds with a principal of 800 million yuan, of which 505.36 million yuan has been repaid, leaving 294.64 million yuan overdue as of December 31, 2023. The latest extension agreement for repayment is set until June 30, 2024 [4]. - The company has calculated that it needs to accrue additional penalties of 20.96 million yuan for 2023 and 9.26 million yuan for the first half of 2024 due to the default situation triggered by the inability to repay the principal [4]. Shareholder Information - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [6].
湖南景峰医药股份有限公司关于公司股票可能被终止上市的第六次风险提示公告
Shang Hai Zheng Quan Bao· 2025-04-10 19:04
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:000908 证券简称:*ST景峰 公告编号:2025-025 湖南景峰医药股份有限公司 关于公司股票可能被终止上市的第六次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗 漏。 特别提示: 1、湖南景峰医药股份有限公司(以下简称"公司")于2024年4月30日披露了《关于公司股票交易被实施 退市风险警示叠加其他风险警示暨股票停复牌的公告》(公告编号:2024-027),公司股票于2024年5 月6日开市起被实施退市风险警示。若公司出现《深圳证券交易所股票上市规则(2024年修订)》(以 下简称《股票上市规则》)第9.3.12条规定的情形,公司股票存在被终止上市的风险。 2、根据《股票上市规则》第9.3.6条的规定,上市公司因触及《股票上市规则》第9.3.1条第一款第一项 至第三项情形,应当在其股票交易被实施退市风险警示当年会计年度结束后,首次披露股票可能被终止 上市的风险提示公告后至年度报告披露前,每十个交易日披露一次风险提示公告。根据上述规定,公司 应当披露股票可能被终止上市的风险提示公告。 ...